RECORD // Company

C4 Therapeutics, Inc.

Built 2026-11-22T00:58:57Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • C4 Therapeutics, Inc · Ca business · same registered legal name as 'C4 Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • C4 Therapeutics, Inc. · Ctgov · same registered legal name as 'C4 Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • C4 THERAPEUTICS INC · Epa echo · same registered legal name as 'C4 Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001628280-26-070575

ItemValuePeriodFormFiledAccessionReport
Revenue$8,468,0003 months ended 2026-09-3010-Q2026-11-050001628280-26-0705752026-11-22 00:58 UTCReport an error
Net income (loss)$-21,843,0003 months ended 2026-09-3010-Q2026-11-050001628280-26-0705752026-11-22 00:58 UTCReport an error
Cash and cash equivalents$32,425,000at 2026-09-3010-Q2026-11-050001628280-26-0705752026-11-22 00:58 UTCReport an error
Contract liabilities (total)$33,281,000at 2026-09-3010-Q2026-11-050001628280-26-0705752026-11-22 00:58 UTCReport an error
Contract liabilities, current$19,516,000at 2026-09-3010-Q2026-11-050001628280-26-0705752026-11-22 00:58 UTCReport an error
Contract liabilities, noncurrent$13,765,000at 2026-09-3010-Q2026-11-050001628280-26-0705752026-11-22 00:58 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001662579
Ticker
CCCC
EIN
475617627
CUSIP
12529R107
Record ID
sx:sec:0001662579

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

35 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:58 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-22 00:58 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:58 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:58 UTCReport an error
Business address490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 024722026-11-16SEC EDGAR company profile2026-11-22 00:58 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:58 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$35,947,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:58 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-104,994,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:58 UTCReport an error
Total assets (at 2025-12-31)$359,075,0002025-12-3110-K, XBRL Assets2026-11-22 00:58 UTCReport an error
Stockholders' equity (at 2025-12-31)$256,587,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:58 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$74,603,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:58 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-98,694,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:58 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$607,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:58 UTCReport an error
Operating lease liabilities (at 2025-12-31)$59,982,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:58 UTCReport an error
Form D total offering amount (D filed 2016-01-11)$73,485,0002016-01-11D2026-11-22 00:58 UTCReport an error
Form D total amount sold (D filed 2016-01-11)$70,315,0002016-01-11D2026-11-22 00:58 UTCReport an error
Form D industry groupBiotechnology2016-01-11D2026-11-22 00:58 UTCReport an error
Form D revenue rangeDecline to Disclose2016-01-11D2026-11-22 00:58 UTCReport an error
Form D date of first sale2015-12-292016-01-11D2026-11-22 00:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, C4 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of…2026-11-05SEC EDGAR 8-K 0001628280-26-070560 (text as filed, excerpt)2026-11-22 00:58 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-25)On September 25, 2026, C4 Therapeutics, Inc. (the “Company”) issued a press release titled “C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting” and posted a corporate presentation on its website at https://ir.c4therapeutics.com/events-presentations. A copy of each of the press release and presentation is furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and…2026-09-25SEC EDGAR 8-K 0001628280-26-063497 (text as filed, excerpt)2026-11-22 00:58 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-25)On September 25, 2026, the Company announced new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma (“RRMM”), as well as preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide in combination with elranatamab (ELREXFIO®), which are being presented in a poster presentation at the 23rd International Myeloma Society (IMS) Annual Meeting. IMS Data Highlights and Cemsidomide Trial Progress Update: Phase 1 Trial of Cemsidomide in Combination with Dexamethasone In 62 heavily pre-treated RRMM patients across the once-daily (QD) dose levels, cemsidomide…2026-09-25SEC EDGAR 8-K 0001628280-26-063497 (text as filed, excerpt)2026-11-22 00:58 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-11)On August 11, 2026 , C4 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange…2026-08-11SEC EDGAR 8-K 0001628280-26-055490 (text as filed, excerpt)2026-11-22 00:58 UTCReport an error
Plan (pension, plan no. 001)C4 THERAPEUTICS, INC. 401(K) PLAN: 176 participants, assets $31,536,5612025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:58 UTCReport an error
Plan (welfare, plan no. 501)C4 THERAPEUTICS, INC. HEALTH AND WELFARE PLAN: 110 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:58 UTCReport an error
Largest institutional holder #1 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$37,360,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$36,877,6722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #3 (13F as filed): Lynx1 Capital Management LP$34,215,6472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #4 (13F as filed): Squadron Capital Management LLC$33,624,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #5 (13F as filed): Bain Capital Life Sciences Investors, LLC$33,492,8202026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #6 (13F as filed): JPMORGAN CHASE & CO$20,651,2952026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$20,630,8042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #8 (13F as filed): CITADEL ADVISORS LLC$19,555,9992026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #9 (13F as filed): GOLDMAN SACHS GROUP INC$16,489,7282026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error
Largest institutional holder #10 (13F as filed): WASATCH ADVISORS LP$16,450,7472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:58 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.